Headline EventAnalyzer: Weekly Market Movers (to 28 Aug 2009)
Source EP Vantage
Company YM BioSciences 
Related: Acorda Therapeutics, Alkermes, Allos Therapeutics, BioCryst Pharmaceuticals, Biovail, Cell Therapeutics, CEL-SCI, Curis, Human Genome Sciences, Immunomedics, Ligand Pharmaceuticals, Myriad Genetics, Novavax, Osiris Therapeutics, Poniard Pharmaceuticals, Rigel Pharmaceuticals, Sangamo BioSciences, Spectrum Pharmaceuticals, Trubion Pharmaceuticals, Valeant Pharmaceuticals International, Vical 
Date August 31, 2009
 

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations. Detailing the previous week’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

      Performance: Fri 28 Aug vs. Fri 21 Aug   
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
1  YM BioSciences   CAD  +103%  105  +53  25 Aug: Shares rise across the week on heavy volumes, peaking at 16.5x average on 25 Aug. 
2  CEL-SCI   USD  +58%  114  +47  20 Aug: Company signs a definitive agreement to raise $4.4m in registered direct offering. 
3  Trubion Pharmaceuticals   USD  +42%  101  +30  28 Aug: Company announces that it has signed a licensing deal worth up to $196.5m with Facet Biotech for global rights to Trubion's phase I chronic lymphocytic leukaemia treatment,  TRU-016; Facet will also buy 2.2m newly issued Trubion shares for $10m.  
4  Immunomedics   USD  +41%  434  +126  27 Aug: Shares rise to a five-year high after company and partner UCB announce phase IIb data for lupus drug,  epratuzumab, in which the drug meets its primary goal of significantly reducing symptoms of the disease versus placebo; analysts also estimate that company could get a $135m in sales milestones if the drug reaches the market and 18% royalty on sales. The company also posts higher-than-expected fiscal Q4 and FY 2009 results mainly due to significant collaboration revenues paid by partner Nycomed, after markets closed.  
5  Curis   USD  +32%  132  +32  28 Aug: Shares surge amid renewed speculation of a takeover, possibly by Roche. The companies are already collaborating in the development of phase II anti cancer drug GDC-0449, designed to block a cell-signalling pathway called hedgehog.  
6  Sanitas   LTL  +26%  124  +26   
7  BioCryst Pharmaceuticals   USD  +25%  484  +97  24 Aug: White House science advisors urge regulators to help companies speed up development and supply of flu drugs and vaccines, and recommend a quicker decision on approval of intravenous versions of antivirals, including BioCryst's peramivir.  
8  Vical   USD  +24%  231  +46  26 Aug: Shares rise amid gains on Swine Flu vaccine stocks as company registers pre-pandemic profits.  
9  Novavax   USD  +24%  535  +103  24 Aug: White House science advisors urge regulators to help companies speed up development and supply of flu drugs and vaccines.
  26 Aug: Shares rise on 3.5x average daily trading volume. 
10  Sangamo BioSciences   USD  +23%  291  +53  25 Aug: JMP Securities maintains its "market outperform" rating and raises price target to $15 from $13, citing optimism over the company's deal with Sigma-Aldrich, announced on 21 Aug, to use zinc finger nuclease technology to develop genetically modified rats for clinical research. 
11  Myriad Genetics   USD  +22%  2941  +541  26 Aug: Canaccord Adams upgrades rating to "buy" from "hold" and raises price target to $35 from $33, citing the company's Q4 & FY 2009 results.
  25 Aug [post-market]: Company reports higher-than-expected fiscal Q4 profits, with molecular diagnostic revenue increasing 33% primarily due to the company's increased sales and marketing efforts, and states that it is comfortable with current market estimates for fiscal 2010. 
12  Poniard Pharmaceuticals   USD  +21%  300  +52  28 Aug: Shares rise on 3x average daily trading volume. 
13  Human Genome Sciences   USD  +20%  3154  +534  25 Aug: Shares rise on rumours of a possible acquisition by the company's partner, GlaxoSmithKline, for $4.1bn or $30 per share; both companies decline to comment. Human Genome Sciences and  GlaxoSmithKline already have collaborations for a number of products, including phase III lupus drug,  Benlysta.  
14  Spectrum Pharmaceuticals   USD  +19%  323  +51  25 Aug: Beacon Equity issues a trading outlook for the company, citing a strong pipeline. 
15  Osiris Therapeutics   USD  +18%  472  +71  24 Aug: Shares jump on 8x average daily volumes. Wall Street Journal cites unnamed analysts attributing the rise to anticipation of phase III results from the company's lead stem cell therapy prochymal, which could be released as early as next week.  

Excludes companies with a market cap. movement of less than US$25m.

Top 15 Losses (%) - ranked on change in share price

      Performance: Fri 28 Aug vs. Fri 21 Aug    
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
1  Rigel Pharmaceuticals   USD  -13%  268  -40  28 Aug: Company's rheumatoid arthritis drug, R788, draws comparison to Merck's Vioxx after physicians suggest that the magnitude of increase in blood pressure in some patients in the  R788 studies is comparable to the increase seen with  Vioxx, which was withdrawn from the market.  
2  Ligand Pharmaceuticals   USD  -12%  275  -37  24 Aug: Company announces it will be buying Neurogen in an $11m all-stock deal, with the potential for additional future payments based on developmental milestones. Ligand will be issuing 4m new shares to fund the acquisition.   
3  XenoPort   USD  -10%  538  -61   
4  Alkermes   USD  -10%  884  -99  26 Aug [post market]: Company discloses in an SEC filing that its partner, Johnson & Johnson, has terminated the development of a four-week long-acting version of antipsychotic drug, risperidone, with analysts speculating that the decision is due to the recent approval of Invega Sustenna and revenue losses to generics; multiple analysts downgrade the stock.  
5  Sucampo Pharmaceuticals   USD  -10%  248  -27   
6  Cell Therapeutics   USD  -8%  844  -71  24 Aug: Shares fall on 2x average daily trading volume. 
7  Optimer Pharmaceuticals   USD  -8%  434  -35   
8  VIVUS   USD  -7%  441  -33   
9  Biovail   USD  -7%  2021  -145  25 Aug: Shares fall after initially rising following the company's announcement on 24 Aug that it was in-licensing US and Canadian development and commercialisation rights to Santhera’s JP-1730 (fipamezole), for the treatment of dyskinesia in Parkinson’s disease; Biovail to make an upfront payment of $8m, milestone payments of up to $35m, and royalty payments of 8-15% on net sales.  
10  Valeant Pharmaceuticals  USD  -6%  2075  -132  24 Aug: The company's drug retigabine fails in phase IIa trials for postherpatic neuralgia. Valeant announces it will continue with a filing of the drug in epilepsy. 
11  Allos Therapeutics   USD  -5%  669  -37  28 Aug: The FDA releases documents ahead of an advisory panel meeting on 2 Sep, questioning the significance of efficacy data submitted by the company for the approval of Folotyn (pralatrexate), for the treatment of peripheral T-cell lymphoma; final decision is due by 24 Sep.  
12  Q-Med   SEK  -5%  540  -28   
13  Amylin Pharmaceuticals   USD  -4%  1823  -80  24 Aug: Company's board of directors unanimously elect former Novartis CEO, Paulo Costa, as chairman.  
14  Acorda Therapeutics   USD  -4%  863  -36  25 Aug: Company announces that the FDA has confirmed that it will hold a panel meeting on 14 Oct to review the company's multiple sclerosis drug, Fampridine SR, and has received preliminary approval for Amaya as the trade name for the drug; the PDUFA date is set as 22 Oct. 
15  Halozyme Therapeutics   USD  -4%  670  -27   

Excludes companies with a market cap. movement of less than US$25m.

Disclaimer:
The above analysis is based on daily share prices supplied to EvaluatePharma Ltd by a third party. EvaluatePharma Ltd accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd